Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

CARDAMYST for Paroxysmal Supraventricular Tachycardia FDA Prescription ... Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib ...

We performed a prospective observational study. Consecutive adult patients undergoing supraventricular tachycardia (SVT) ablation or curative left atrial ablation for paroxysmal AF over a 1-year ...

A recent study links morning coffee consumption to lower death rates from cardiovascular problems. A Fort Worth cardiologist ...

Commonly it will be an actual abnormal heart rhythm - anything from extra beats like PVCs (premature ventricular contraction) to arrhythmias like atrial fibrillation, atrial flutter or SVT ...

CARDAMYST for Paroxysmal Supraventricular Tachycardia FDA Prescription ... Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib ...

The most common causes of a cough that lasts as long as yours are reflux, postnasal drip and asthma. The ENT can almost always diagnose postnasal drip with an endoscopy. However, I suspect something ...

It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...

You make a compelling case that metoprolol is a major cause of your cough now, but I don’t think it’s the only one.

This patent pertains to the repeat dose regimen of CARDAMYST™, which demonstrated efficacy in the RAPID Phase 3 study for paroxysmal supraventricular tachycardia (PSVT). The issuance of this ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...